AB5644

Anti-EGFR (phospho Y1068)抗体

Name: EGFR(磷酸化Y1068)抗体 (ab5644)| Abcam中文官网
Brand: Abcam Limited
SKU: AB5644
Price: 5014 CNY
Availability: InStock
Rating: 4 (5 reviews)

Anti-EGFR (phospho Y1068) antibody

Lab Essentials
了解详情

(5 Reviews)

(52 Publications)

Rabbit Polyclonal EGFR phospho Y1068 antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 52 publications. Immunogen corresponding to Synthetic Peptide within Human EGFR phospho Y1068 + Y1068.

查看别名

ERBB, ERBB1, HER1, EGFR, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1

3 Images

Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1068) antibody (AB5644)

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-EGFR (phospho Y1068) antibody (AB5644)

Immunofluorescence analysis of A431 (Human epidermoid carcinoma cell line) cells labeling EGFR with ab5644 at 1/100 dilution, followed by Goat anti-rabbit IgG (H+L) Superclonal, Alexa Fluor® 488 conjugate was used as the secondary antibody at 1/2000 dilution (Panel a). Nuclei (Panel b) were stained with SlowFade^® Gold Antifade Mountant with DAPI. F-actin (Panel c) was stained with Rhodamine Phalloidin. Panel (d) represents the merged image showing membrane localization. Panel (e) represents cells treated with antagonist, Afatinib (1μM for 6hrs) followed by EGF (200 ng/ml for 10 minutes), showing no Phospho-EGFR staining. Panel (f) shows untreated cells with no signal. Panel (g) represents control cells with no primary antibody to assess background.

The cells (in 70% confluent log phase treated with 200ng/ml of EGF for 10 minutes) were fixed with 4% paraformaldehyde for 10 minutes; permeabilized with 0.1% Triton X-100 for 10 minutes and blocked with 1% BSA for hour at room temperature. The images were captured at 60X magnification.

Supplier Data

Western blot - Anti-EGFR (phospho Y1068) antibody (AB5644)

Western blot analysis using ab5644 shows increased expression of proteins phosphorylated at the tyrosine residues in A-431 and A549 cell lines upon EGF treatment and pre-treatment with EGFR-antagonists, Gefitinib and Afatinib. This results in inhibition of Phospho-EGFR in A-431 and A549 cell lines

All lanes:

Western blot - Anti-EGFR (phospho Y1068) antibody (ab5644) at 1/1000 dilution

Lane 1:

A431 (Human epidermoid carcinoma cell line) whole cell lysate at 30 µg

Lane 2:

A431 whole cell lysate treated with EGF (200 ng/mL for 10 minutes) at 30 µg

Lane 3:

A431 whole cell lysate treated with Gefitinib followed by EGF (1uM for 16 hours, 200 ng/mL for 10 minutes) at 30 µg

Lane 4:

A431 whole cell lysate treated with Afatinib followed by EGF (0.5 uM for 6 hours, 200 ng/mL for 10 minutes) at 30 µg

Lane 5:

A549 (Human lung carcinoma cell line) whole cell lysate at 30 µg

Lane 6:

A549 whole cell lysate treated with EGF (200 ng/mL for 10 minutes) at 30 µg

Lane 7:

A549 whole cell lysate treated with Afatinib followed by EGF (0.5 uM for 6 hours, 200 ng/mL for 10 minutes) at 30 µg

Secondary

All lanes:

Goat anti-Rabbit IgG Superclonal Secondary Antibody, HRP at 1/4000 dilution

Predicted band size: 134 kDa

false

AbReview5553****

Western blot - Anti-EGFR (phospho Y1068) antibody (AB5644)

All lanes:

Western blot - Anti-EGFR (phospho Y1068) antibody (ab5644) at 1/200 dilution

Lane 1:

A431 (Human epidermoid carcinoma cell line) whole cell lysate - not treated

Lane 2:

A431 whole cell lysate - 100ng/ml EGF for 1 minute

Lane 3:

A431 whole cell lysate - 100ng/ml EGF for 2.5 minutes

Lane 4:

A431 whole cell lysate - 100ng/ml EGF for 5 minutes

Lane 5:

A431 whole cell lysate - 100ng/ml EGF for 10 minutes

Lane 6:

A431 whole cell lysate - 100ng/ml EGF for 20 minutes

Lane 7:

A431 whole cell lysate - 100ng/ml EGF for 40 minutes

Secondary

All lanes:

HRP conjugated Goat anti-rabbit antibody

Predicted band size: 134 kDa

true

Exposure time: 2min

This image is courtesy of an Abreview submitted by Mr Samir Nuseibeh

关键信息

宿主种属

Rabbit

克隆

Polyclonal

亚型

IgG

不含载体蛋白

反应种属

Human

应用

WB, ICC/IF

applications

免疫原

Synthetic Peptide within Human EGFR phospho Y1068 + Y1068. The exact immunogen used to generate this antibody is proprietary information.

P00533

style

left-column

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p></p>" } } }

style

left-column

style

left-column

性能和储存信息

形式

Liquid

纯化工艺

Affinity purification Immunogen

纯化说明

The antibody has been negatively preadsorbed using (i) a non phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated epidermal growth factor receptor (EGFR), and (ii) a generic tyrosine phosphorylated peptide to remove antibody that is reactive with phosphotyrosine, irrespective of the sequence. The final product is generated by affinity chromatography using an EGFR-derived peptide that is phosphorylated at tyrosine 1068.

存储溶液

pH: 7.3 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA

运输条件

Blue Ice

分装信息

Upon delivery aliquot

储存信息

Avoid freeze / thaw cycle

style

left-column

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

EGFR or Epidermal Growth Factor Receptor is a transmembrane glycoprotein that acts as a receptor for members of the epidermal growth factor family. Known alternatively as ErbB1 or HER1 this receptor has an approximate molecular weight of 170 kDa. EGFR is expressed in various cell types notably on epithelial cells and can influence multiple cellular processes through its kinase activity. It participates in the regulation of cell growth multiplication and survival by activating its kinase domain upon ligand binding.

Biological function summary

The EGFR protein plays an important role in cellular communication and signaling processes. EGFR pairs with other receptor family members to form active dimers or even higher-order complexes which in turn initiate intracellular signaling cascades. Through these complexes EGFR influences many processes including cell differentiation and repair. This function of EGFR makes it an integral part of mammalian biology affecting how cells respond to their environment by mediating changes in gene expression.

Pathways

EGFR is a central player in the MAPK and PI3K/Akt signaling pathways. Alongside other protein partners like KRAS and PI3 kinase it contributes to transmitting signals from the cell surface to the nucleus affecting gene transcription and cell behavior. These pathways are important for normal cell growth and division and aberrations in these pathways can lead to excessive or insufficient cell proliferation.

EGFR is pertinent to cancer biology including non-small cell lung cancer and glioblastoma where mutations or overexpression of the receptor frequently occur. It connects to proteins such as PTEN and BRAF which influence tumor progression and response to targeted therapies. EGFR's involvement in these disorders highlights its significance as a therapeutic target since it can be manipulated to alter disease progression.

style

left-column

style

left-column

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

靶点信息

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed : 10805725, PubMed : 27153536, PubMed : 2790960, PubMed : 35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed : 12297049, PubMed : 15611079, PubMed : 17909029, PubMed : 20837704, PubMed : 27153536, PubMed : 2790960, PubMed : 7679104, PubMed : 8144591, PubMed : 9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed : 27153536). May also activate the NF-kappa-B signaling cascade (PubMed : 11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed : 11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed : 11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed : 20462955). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity).. Isoform 2 may act as an antagonist of EGF action.. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

See full target information EGFR phospho Y1068

style

left-column

文献 (52)

Recent publications for all applications. Explore the full list and refine your search

International journal of molecular sciences 24: PubMed37762316

2023

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.

Applications

Unspecified application

Species

Unspecified reactive species

Yanping Huang,Xiangdan Cuan,Weiwei Zhu,Xingying Yang,Yunli Zhao,Jun Sheng,Chengting Zi,Xuanjun Wang

International archives of allergy and immunology 184:1010-1021 PubMed37336194

2023

The ERBB2 Exonic Variant Pro1170Ala Modulates Mitogen-Activated Protein Kinase Signaling Cascades and Associates with Allergic Asthma.

Applications

Unspecified application

Species

Unspecified reactive species

Yang Yie Sio,Wei Liang Gan,Wing Shan Ng,Sri Anusha Matta,Yee-How Say,Keng Foo Teh,Yi Ru Wong,Smyrna Moti Rawanan Shah,Kavita Reginald,Fook Tim Chew

The Journal of biological chemistry 299:104814 PubMed37178919

2023

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Xuan Hong,Min-Tsang Hsieh,Tzu-Yu Tseng,Hui-Yi Lin,Hung-Chih Chang,Sir-Theng Yau,Wei-Chung Cheng,Baozhen Ke,Hsiao-Hui Liao,Chih-Ying Wu,An-An Liu,Meei-Maan Wu,Kuo-Yen Huang,Pan-Chyr Yang,Sheng-Chu Kuo,Mien-Chie Hung,Pei-Chih Lee

iScience 26:106089 PubMed36876120

2023

CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yu-Chuan Lin,Chun-Hung Hua,Hsin-Man Lu,Shi-Wei Huang,Yeh Chen,Ming-Hsui Tsai,Fang-Yu Lin,Peter Canoll,Shao-Chih Chiu,Wei-Hua Huang,Der-Yang Cho,Chia-Ing Jan

Cell reports 39:110993 PubMed35732135

2022

KRAS-independent feedback activation of wild-type RAS constrains KRAS inhibitor efficacy.

Applications

Unspecified application

Species

Unspecified reactive species

Meagan B Ryan,Oluwadara Coker,Alexey Sorokin,Katerina Fella,Haley Barnes,Edmond Wong,Preeti Kanikarla,Fengqin Gao,Youyan Zhang,Lian Zhou,Scott Kopetz,Ryan B Corcoran

Cancers 13: PubMed34944934

2021

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Isabel Mayayo-Peralta,Beatrice Faggion,Liesbeth Hoekman,Ben Morris,Cor Lieftink,Isabella Goldsbrough,Lakjaya Buluwela,Joseph C Siefert,Harm Post,Maarten Altelaar,Roderick Beijersbergen,Simak Ali,Wilbert Zwart,Stefan Prekovic

Cancer cell 39:1531-1547.e10 PubMed34624218

2021

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

Applications

Unspecified application

Species

Unspecified reactive species

Haichuan Hu,Zofia Piotrowska,Patricia J Hare,Huidong Chen,Hillary E Mulvey,Aislinn Mayfield,Sundus Noeen,Krystina Kattermann,Max Greenberg,August Williams,Amanda K Riley,Jarad J Wilson,Ying-Qing Mao,Ruo-Pan Huang,Mandeep K Banwait,Jeffrey Ho,Giovanna S Crowther,Lida P Hariri,Rebecca S Heist,David P Kodack,Luca Pinello,Alice T Shaw,Mari Mino-Kenudson,Aaron N Hata,Lecia V Sequist,Cyril H Benes,Matthew J Niederst,Jeffrey A Engelman

Cancers 13: PubMed34359721

2021

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress.

Applications

Unspecified application

Species

Unspecified reactive species

Virginia Napolitano,Daniela Russo,Francesco Morra,Francesco Merolla,Silvia Varricchio,Gennaro Ilardi,Rosa Maria Di Crescenzo,Francesco Martino,Massimo Mascolo,Angela Celetti,Luca Tamagnone,Stefania Staibano

Scientific reports 11:8016 PubMed33850249

2021

Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass.

Applications

Unspecified application

Species

Unspecified reactive species

Mark Borris D Aldonza,Roben D Delos Reyes,Young Seo Kim,Jayoung Ku,Ana Melisa Barsallo,Ji-Young Hong,Sang Kook Lee,Han Suk Ryu,YongKeun Park,Je-Yoel Cho,Yoosik Kim

Nature communications 12:1261 PubMed33627640

2021

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hayato Mizuta,Koutaroh Okada,Mitsugu Araki,Jun Adachi,Ai Takemoto,Justyna Kutkowska,Kohei Maruyama,Noriko Yanagitani,Tomoko Oh-Hara,Kana Watanabe,Keiichi Tamai,Luc Friboulet,Kazuhiro Katayama,Biao Ma,Yoko Sasakura,Yukari Sagae,Mutsuko Kukimoto-Niino,Mikako Shirouzu,Satoshi Takagi,Siro Simizu,Makoto Nishio,Yasushi Okuno,Naoya Fujita,Ryohei Katayama

View all publications

style

left-column

style

left-column

style

right-column